|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||198.226 g·mol−1|
|3D model (JSmol)|
Mebicar (mebicarum) is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in Latvia and Russia under the brand name Adaptol. Mebicar is not approved for use in the United States.
Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.
Mebicar purportedly has anti-anxiety (anxiolytic) properties. It is also used to aid smoking cessation. In addition, mebicar may be useful in the treatment of ADHD symptoms. In contrast with typical anxiolytic medications such as benzodiazepines, mebicar is non-habit forming, non-sedating and does not impair motor function.